Prestige Consumer Healthcare Inc. (NYSE:PBH) Receives Consensus Rating of “Hold” from Analysts

Prestige Consumer Healthcare Inc. (NYSE:PBH) has been given an average recommendation of “Hold” by the seven brokerages that are presently covering the firm, MarketBeat.com reports. Four analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $80.60.

Several analysts recently weighed in on PBH shares. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Prestige Consumer Healthcare in a report on Thursday, January 22nd. Canaccord Genuity Group reduced their price objective on shares of Prestige Consumer Healthcare from $100.00 to $88.00 and set a “buy” rating on the stock in a report on Friday, November 7th. Jefferies Financial Group decreased their price objective on shares of Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating for the company in a research report on Friday, January 30th. Finally, Zacks Research raised Prestige Consumer Healthcare from a “strong sell” rating to a “hold” rating in a report on Monday, November 10th.

Insider Activity

In other news, VP Jeffrey Zerillo sold 1,000 shares of the stock in a transaction dated Wednesday, February 11th. The stock was sold at an average price of $65.93, for a total value of $65,930.00. Following the transaction, the vice president owned 41,048 shares in the company, valued at approximately $2,706,294.64. This represents a 2.38% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 1.40% of the company’s stock.

Institutional Investors Weigh In On Prestige Consumer Healthcare

Hedge funds and other institutional investors have recently bought and sold shares of the stock. UMB Bank n.a. lifted its position in Prestige Consumer Healthcare by 110.1% in the fourth quarter. UMB Bank n.a. now owns 418 shares of the company’s stock valued at $26,000 after acquiring an additional 219 shares during the last quarter. Bayforest Capital Ltd acquired a new stake in shares of Prestige Consumer Healthcare during the fourth quarter worth about $29,000. First Horizon Corp purchased a new stake in shares of Prestige Consumer Healthcare in the 3rd quarter valued at about $32,000. Barrow Hanley Mewhinney & Strauss LLC boosted its position in shares of Prestige Consumer Healthcare by 106.8% in the 3rd quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 548 shares of the company’s stock valued at $34,000 after purchasing an additional 283 shares during the period. Finally, Torren Management LLC acquired a new stake in shares of Prestige Consumer Healthcare in the 4th quarter valued at about $35,000. 99.95% of the stock is currently owned by institutional investors and hedge funds.

Prestige Consumer Healthcare Trading Up 0.9%

NYSE:PBH opened at $69.14 on Wednesday. Prestige Consumer Healthcare has a 12-month low of $57.25 and a 12-month high of $90.04. The firm has a market cap of $3.27 billion, a PE ratio of 18.29, a price-to-earnings-growth ratio of 2.16 and a beta of 0.41. The company has a current ratio of 3.11, a quick ratio of 1.93 and a debt-to-equity ratio of 0.58. The stock has a fifty day moving average price of $65.52 and a 200 day moving average price of $63.51.

Prestige Consumer Healthcare (NYSE:PBH) last issued its quarterly earnings results on Thursday, February 5th. The company reported $1.14 earnings per share for the quarter, missing the consensus estimate of $1.16 by ($0.02). The company had revenue of $283.44 million for the quarter, compared to analysts’ expectations of $286.93 million. Prestige Consumer Healthcare had a return on equity of 12.02% and a net margin of 16.90%.Prestige Consumer Healthcare’s revenue for the quarter was down 2.4% compared to the same quarter last year. During the same quarter last year, the company earned $1.22 EPS. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.540 EPS. Sell-side analysts anticipate that Prestige Consumer Healthcare will post 4.5 earnings per share for the current fiscal year.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).